Vaxart Independent Directors Urge Shareholder Vote for Current Board Amid Proxy Contest
VXRT has more than doubled off its 52-week low of $0.261.
Summary
Vaxart's two newest independent directors issued a letter to shareholders, urging them to vote for the company's current director nominees on the WHITE proxy card ahead of the July 16, 2026 Annual Meeting, defending the board against a dissident shareholder group.
Key Events · Corporate Governance and Compliance · VXRT
-
Independent Directors Appeal to Shareholders
Vaxart's two newest independent directors, James Breitmeyer and Kevin Finney, sent a letter urging shareholders to vote "FOR" all six of the company's director nominees on the WHITE proxy card for the upcoming Annual Meeting.
-
Defense Against Dissident Shareholder Group
The letter directly addresses the ongoing proxy contest, arguing that replacing current directors with "unqualified nominees" would undermine the company's ability to advance its programs and secure financial resources.
-
Emphasis on Board Experience and Accountability
The directors highlight their combined 70+ years of biotech experience and commitment to holding management accountable, citing the board's role in securing funding, strengthening financials, and extending the company's runway.
-
Annual Meeting Scheduled
The Annual Meeting of Stockholders, where the director elections will take place, is scheduled for July 16, 2026.
Analysis · VXRT · Life Sciences
This DEFA14A is a direct communication from Vaxart's newest independent directors to shareholders, intensifying the ongoing proxy contest. It aims to solidify support for the current board by emphasizing their experience, accountability, and successful navigation of past challenges, including alleviating a "going concern" warning. The outcome of the July 16th Annual Meeting will determine the company's leadership and strategic direction, making this a critical update in the battle for board control.
At the time of this filing, VXRT was trading at $0.56 on OTC in the Life Sciences sector, with a market capitalization of approximately $139.2M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.